Upper Gastrointestinal CancerNCT07462247
Establishment of Image Database for Early Upper Gastrointestinal Cancer, Precancerous Lesions, and Precancerous Conditions
An observational study of Upper Gastrointestinal Cancer and Upper Gastrointestinal Precancerous Lesions, run by Changhai Hospital at 1 site in China.
Trial summary
The study is designed to collect magnetically-controlled capsule endoscopy (MCE) images, esophagogastroduodenoscopy (EGD) images, CT images, and histopathology results to establish a database for early upper gastrointestinal cancer, precancerous lesions, and precancerous conditions. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Upper Gastrointestinal Cancer, Upper Gastrointestinal Precancerous Lesions, Upper Gastrointestinal Precancerous Conditions
- What is being tested?
- ESD, biopsy
- Type of treatment
- Pill or oral medicine, Surgery or procedure
- How many people
- 500 participants
- Where
- 1 siteChina
- Study dates
- 11 Mar 2026to Dec 2030
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Tertiary Hospital
Who may be able to join
- Male or female participants aged ≥ 18 years
- Patients with early upper gastrointestinal cancer referred for endoscopic submucosal dissection (ESD), or patients with upper gastrointestinal precancerous lesions or precancerous conditions referred for biopsy by esophagogastroduodenoscopy (EGD)
- Participants who are willing and able to participate in this study, complete all required examinations and follow-up visits, and who have provided written informed consent
Who cannot join
- Patients who are not eligible for surgery or who refuse any abdominal surgery in case of capsule retention and endoscopic retrieval failure
- Patients with cardiac pacemaker or other implanted electromedical devices which could interfere with magnetic resonance
- Suspected or known intestinal stenosis or other known risk factors for capsule retention
- Patients with dysphagia
- Pregnancy
- Allergy to polymeric materials, latex, simethicone, or pronase
- Patients plan to undergo magnetic resonance imaging examination before excretion of the capsule
- Patients with any condition that precludes compliance with the study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Changhai Hosptial
Shanghai, 200433
Jun Pan, MD, +86-13764598567, panjun059@163.com
About this study
The study is designed to collect magnetically-controlled capsule endoscopy (MCE) images, esophagogastroduodenoscopy (EGD) images, CT images, and histopathology results to establish a database for early upper gastrointestinal cancer, precancerous lesions, and precancerous conditions.
Read the detailed description
Images of MCE for UGIC are scarce, limiting the development of corresponding AI diagnostic model. We aim to create an image database with MCE images, EGD images, CT images, and histopathology results, in patients treated by ESD for early upper gastrointestinal cancer, or biopsy for precancerous lesions, and precancerous conditions, so as to facilitate image-based deep learning studies.
- Conditions
- Upper Gastrointestinal Cancer, Upper Gastrointestinal Precancerous Lesions, Upper Gastrointestinal Precancerous Conditions
- Being tested
- magnetically-controlled capsule endoscopy, esophagogastroduodenoscopy, CT scan, ESD, biopsy
- Keywords
- image database, upper gastrointestinal cancer
- Medical subject headings
- Gastrointestinal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
magnetically-controlled capsule endoscopy, esophagogastroduodenoscopy, CT scanDiagnostic test
Magnetically-controlled capsule endoscopy (MCE) images, esophagogastroduodenoscopy (EGD) images, and CT images for early upper gastrointestinal cancer, precancerous lesions, and precancerous conditions
ESD, biopsyProcedure or surgery
ESD or biopsy for histopathology results
What is being measured
The primary outcome is the main question the study is designed to answer.
Magnetically-controlled capsule endoscopy (MCE) images, esophagogastroduodenoscopy (EGD) images, and CT images
Measured: Prior to ESD or biopsy
Histopathology results
Measured: During ESD or biopsy
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Mar 2026
- Study start11 Mar 2026
- Primary completionDec 2030 (estimated)
- Study completionDec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Upper Gastrointestinal CancerStudies of the same condition, open and under way.
- More trials run by Changhai HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Changhai Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jun Pan, Changhai Hospital
- Investigators
- Jun Pan, MD, Principal investigator, Changhai Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07462247
- Sponsor's protocol ID
- CHEC2026-069
- Status last verified
- Mar 2026
- First submitted
- 5 Mar 2026
- Last updated
- 12 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 12 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Establishment of Image Database for Early Upper Gastrointestinal Cancer, Precancerous Lesions, and Precancerous Conditions
- ClinicalTrials.gov ID
- NCT07462247
- Acronym / sponsor ID
- CHEC2026-069
- Conditions
- Upper Gastrointestinal Cancer, Upper Gastrointestinal Precancerous Lesions, Upper Gastrointestinal Precancerous Conditions
- Keywords
- image database, upper gastrointestinal cancer
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Changhai HospitalUniversity, hospital or other
- Study start
- 11 Mar 2026 (actual)
- Primary completion
- Dec 2030 (estimated)
- Study completion
- Dec 2030 (estimated)
- First posted
- 10 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study is designed to collect magnetically-controlled capsule endoscopy (MCE) images, esophagogastroduodenoscopy (EGD) images, CT images, and histopathology results to establish a database for early upper gastrointestinal cancer, precancerous lesions, and precancerous conditions.
Detailed description
Images of MCE for UGIC are scarce, limiting the development of corresponding AI diagnostic model. We aim to create an image database with MCE images, EGD images, CT images, and histopathology results, in patients treated by ESD for early upper gastrointestinal cancer, or biopsy for precancerous lesions, and precancerous conditions, so as to facilitate image-based deep learning studies.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Tertiary Hospital
Key inclusion criteria (3 listed)
- Male or female participants aged ≥ 18 years
- Patients with early upper gastrointestinal cancer referred for endoscopic submucosal dissection (ESD), or patients with upper gastrointestinal precancerous lesions or precancerous conditions referred for biopsy by esophagogastroduodenoscopy (EGD)
- Participants who are willing and able to participate in this study, complete all required examinations and follow-up visits, and who have provided written informed consent
Key exclusion criteria (8 listed)
- Patients who are not eligible for surgery or who refuse any abdominal surgery in case of capsule retention and endoscopic retrieval failure
- Patients with cardiac pacemaker or other implanted electromedical devices which could interfere with magnetic resonance
- Suspected or known intestinal stenosis or other known risk factors for capsule retention
- Patients with dysphagia
- Pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| magnetically-controlled capsule endoscopy, esophagogastroduodenoscopy, CT scanMagnetically-controlled capsule endoscopy (MCE) images, esophagogastroduodenoscopy (EGD) images, and CT images for early upper gastrointestinal cancer, precancerous lesions, and precancerous conditions | Diagnostic test | – |
| ESD, biopsyESD or biopsy for histopathology results | Procedure or surgery | – |
Primary outcome
Magnetically-controlled capsule endoscopy (MCE) images, esophagogastroduodenoscopy (EGD) images, and CT images
Time frame: Prior to ESD or biopsy
Histopathology results
Time frame: During ESD or biopsy
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Mar 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Upper Gastrointestinal Cancer
Enrolling by invitation
Immunonutrition for Surgical Prehabilitation of Patients With Upper GI Cancer
Upper GI Cancer
Active, not recruitingPhase 1/2
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer
Recruiting
Clinical Study on Using Laparoscopic Sentinel Lymph Node Navigation Combined With Dual Endoscopy Surgery for Early Gastric Cancer
Early-stage Upper Gastrointestinal Cancer, Stomach Cancer, Adenocarcinoma
Not yet recruiting
Prehabilitation for Upper Gastrointestinal Tract Cancer Surgery
Surgery of Upper Gastrointestinal Tract Cancer
Active, not recruitingPhase 2
A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jun Pan, MD principal investigator
Changhai Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Upper Gastrointestinal Cancer and Upper Gastrointestinal Precancerous Lesions, run by Changhai Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 12 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jun Pan, MD (+86-13764598567, panjun059@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Magnetically-controlled capsule endoscopy (MCE) images, esophagogastroduodenoscopy (EGD) images, and CT images (time frame: Prior to ESD or biopsy). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2026.